TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05231538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: stretching, passive range of motion, and active range of motion).
Study: NCT04677049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin CRT
Description: A controlled release technology (CRT) tablet of Niacin
Study: NCT05984628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: blank solvent
Description: After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
Study: NCT04954833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-118
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-118
Description: CONTROL Lens
Study: NCT05799209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Float Pool
Description: Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Float Chair
Description: Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
Study: NCT06462404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.
Study: NCT06204289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Supportive Care Programme
Description: Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
Study: NCT06462404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.
Study: NCT04829110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETOH
Description: Participants will consume Vodka

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETOH
Description: Participants will consume Vodka
Study: NCT06462404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086 Placebo
Description: E2086 matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Active comparator oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.
Study: NCT05865210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kegel Exercise
Description: Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel Exercise
Description: Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Description: Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
Study: NCT05041062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
Study: NCT04848597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: 200mg , once every 3 weeks
Study: NCT05037071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper body graduated compression sleeve
Description: An over the counter light compression sleeve will be worn during game training
Study: NCT06462404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator Placebo
Description: Active comparator matching placebo tablet.
Study: NCT04614909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60mg administered orally BID for 4 days prior to surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60mg administered orally BID for 4 days prior to surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 200mg administered orally BID for 4 days prior to surgical resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
Study: NCT04897022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Fixed dose of pembrolizumab 200mg IV q3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMPRINT
Description: The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
Study: NCT06443892

Intervention type: PROCEDURE
Intervention: Pericapsular Nerve Block (PENG)
Description: Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.

Intervention type: PROCEDURE
Intervention: Suprainguinal Fascia Iliaca Compartment Block (SFICB)
Description: Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
Study: NCT06048809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)
Description: Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Fluoride Toothpaste (Colgate Cavity Protection)
Description: Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
Study: NCT04871477

Intervention type: OTHER
Intervention: Communication Intervention
Description: Audio record part of clinic visit

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06249841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1.1mm flexible Cryoprobe SU
Description: Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
Study: NCT04765956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon treatment
Description: Drug-eluting balloon (DEB) treatment of lipid-rich plaque
Study: NCT05870670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Administered subcutaneously.
Study: NCT06249841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1.1mm flexible Cryoprobe SU
Description: Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
Study: NCT06138899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Club 25
Description: The Club 25 donation program will involve students pledging to donate blood 25 times in their lifetime. In order to achieve this objective, students also pledge to lead a healthy lifestyle, to avoid acquiring HIV and other TTIs and to continue donating blood after leaving school. The Club 25 donation program includes activities in-between blood donation events as well as peer leadership and peer education in schools and in communities.
Study: NCT05870670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously.
Study: NCT05571904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thick STSG; thin STSG
Description: For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thick STSG; thin STSG
Description: For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients.
Study: NCT06788223

Intervention type: DEVICE
Intervention: Parathyroidectomy
Description: Parathyroidectomy under general anesthesia

Intervention type: DEVICE
Intervention: Parathyroidectomy
Description: Parathyroidectomy under general anesthesia
Study: NCT06524635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection
Study: NCT04829110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Participants will consume sucrose in solution with water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Participants will consume sucrose in solution with water
Study: NCT06060496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
Study: NCT05994001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilizumab
Description: cardonilizumab:PD1 and CTLA-4 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilizumab
Description: cardonilizumab:PD1 and CTLA-4 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 :ClAUDIN 18.2-ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 :ClAUDIN 18.2-ADC
Study: NCT06160297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Otago Exercise
Description: The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercise
Description: * Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair
Study: NCT05237336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Cognitive Therapy
Description: MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counselling as usual
Description: Control group, Counselling as usual
Study: NCT04683744

Intervention type: OTHER
Intervention: Semi-structured interviews-Patients
Description: The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.

Intervention type: OTHER
Intervention: Semi-structured interviews-Health system
Description: The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
Study: NCT04964518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG 2575 ramp up arm
Description: APG2575 ramp up + Azacitidine
Study: NCT06060496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes